Uni-Bio Science Group Limited (HKG: 0690), a China-based company, announced on September 12, 2025, that it has entered into a strategic cooperation agreement with Sinovac Pharmaceutical (SHA: 688136). Under the agreement, Uni-Bio’s subsidiary, Beijing GeneTech Pharma, has granted Sinovac exclusive commercialization rights for Teriparatide Injection in six international markets: Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. The product is expected to complete registration and generate sales revenue in these regions as early as the end of 2026.
Product Profile
Teriparatide is a recombinant human parathyroid hormone analog (PTH1−34) used as an anabolic treatment for osteoporosis. Launched in China in March 2024, it achieved significant commercial success, generating revenue of approximately HK$65.6 million in the first half of 2025, marking a 248.9% year-on-year increase.
Market Expansion
Uni-Bio Science’s strategic partnership with Sinovac highlights the global potential of Teriparatide Injection. The collaboration aims to leverage Sinovac’s market presence to drive the product’s international growth and market penetration.-Fineline Info & Tech
